Multiple myeloma in the marrow: pathogenesis and treatments

Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease

(2016) Homare Eda et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Small interfering RNA silencing of interleukin-6 in mesenchymal stromal cells inhibits multiple myeloma cell growth

(2016) Hoon Koon Teoh et al.   LEUKEMIA RESEARCH

Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials

(2016) Heleen H. Van Acker et al.   PHARMACOLOGY & THERAPEUTICS

Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma

(2015) J. J. Shah et al.   BLOOD

Dynamic interplay between bone and multiple myeloma: Emerging roles of the osteoblast

(2015) Michaela R. Reagan et al.   BONE

Anti-DKK1 antibody promotes bone fracture healing through activation of β-catenin signaling

(2015) Hongting Jin et al.   BONE

Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma

(2015) David H. Vesole et al.   BRITISH JOURNAL OF HAEMATOLOGY

From CLL to Multiple Myeloma - Spleen Tyrosine Kinase (SYK) influences multiple myeloma cell survival and migration

(2015) Joschka Lorenz et al.   BRITISH JOURNAL OF HAEMATOLOGY

A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma

(2015) M. Hansson et al.   CLINICAL CANCER RESEARCH

A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

(2015) Naveen Pemmaraju et al.   Clinical Lymphoma Myeloma & Leukemia

Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial

(2015) Katja Weisel et al.   Clinical Lymphoma Myeloma & Leukemia

Immunotherapy for multiple myeloma: Current status and future directions

(2015) Ayed O. Ayed et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Molecular pathogenesis of multiple myeloma

(2015) Yusuke Furukawa et al.   International Journal of Clinical Oncology

Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine

(2015) Vittorio Simeon et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies

(2015) Matthew T. Burger et al.   JOURNAL OF MEDICINAL CHEMISTRY

Bone remodeling in the context of cellular and systemic regulation: the role of osteocytes and the nervous system

(2015) Tadeusz Niedźwiedzki et al.   JOURNAL OF MOLECULAR ENDOCRINOLOGY

Multiple myeloma

(2015) Christoph Röllig et al.   LANCET

Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial

(2015) Francesca Gay et al.   LANCET ONCOLOGY

Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group

(2015) J Laubach et al.   LEUKEMIA

Navigating the bone marrow niche: translational insights and cancer-driven dysfunction

(2015) Michaela R. Reagan et al.   Nature Reviews Rheumatology

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

(2015) Sagar Lonial et al.   NEW ENGLAND JOURNAL OF MEDICINE

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

(2015) A. Keith Stewart et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

(2015) Henk M. Lokhorst et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma

(2015) M B Meads et al.   ONCOGENE

Whole Genome Sequence of Multiple Myeloma-Prone C57BL/KaLwRij Mouse Strain Suggests the Origin of Disease Involves Multiple Cell Types

(2015) Sarah R. Amend et al.   PLoS One

Protein C-terminal enzymatic labeling identifies novel caspase cleavages during the apoptosis of multiple myeloma cells induced by kinase inhibition

(2015) Wenwen Duan et al.   PROTEOMICS

American Society of Hematology Annual Meeting 2014: highlights in multiple myeloma

(2015) Siobhan V Glavey et al.   Expert Review of Hematology

Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche

(2015) Michelle A. Lawson et al.   Nature Communications

A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies

(2015) S Y Kim et al.   Blood Cancer Journal

Phase I safety data of lenalidomide, bortezomib, dexamethasone and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211

(2015) S Z Usmani et al.   Blood Cancer Journal

Capsaicin inhibits the adipogenic differentiation of bone marrow mesenchymal stem cells by regulating cell proliferation, apoptosis, oxidative and nitrosative stress

(2015) Muhammed Ibrahim et al.   Food & Function

SC06, a novel small molecule compound, displays preclinical activity against multiple myeloma by disrupting the mTOR signaling pathway

(2015) Kunkun Han et al.   Scientific Reports

CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation

(2015) Aldo M. Roccaro et al.   Cell Reports

Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease

(2015) Emily Ashjian et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells

(2015) Rikio Suzuki et al.   PLoS One

Osteoblastic niche supports the growth of quiescent multiple myeloma cells

(2014) Z. Chen et al.   BLOOD

The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma

(2014) S. V. Glavey et al.   BLOOD

Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model

(2014) M. R. Reagan et al.   BLOOD

Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations

(2014) C. Pawlyn et al.   BLOOD

Pyk2 promotes tumor progression in multiple myeloma

(2014) Y. Zhang et al.   BLOOD

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

(2014) P. G. Richardson et al.   BLOOD

Endocrine, metabolic, nutritional and body composition abnormalities are common in advanced intensively-treated (transplanted) multiple myeloma

(2014) D M Greenfield et al.   BONE MARROW TRANSPLANTATION

Stimulation of invariant natural killer T cells by α-Galactosylceramide activates the JAK-STAT pathway in endothelial cells and reduces angiogenesis in the 5T33 multiple myeloma model

(2014) Haneen Nur et al.   BRITISH JOURNAL OF HAEMATOLOGY

Recent advances and future directions in targeting the secretory apparatus in multiple myeloma

(2014) Holger W. Auner et al.   BRITISH JOURNAL OF HAEMATOLOGY

Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastases

(2014) Aimalie L. Hardaway et al.   CANCER AND METASTASIS REVIEWS

Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

(2014) Jens G. Lohr et al.   CANCER CELL

Phosphoinositide Protein Kinase PDPK1 Is a Crucial Cell Signaling Mediator in Multiple Myeloma

(2014) Y. Chinen et al.   CANCER RESEARCH

Contributions of the Host Microenvironment to Cancer-Induced Bone Disease

(2014) Sam W.Z. Olechnowicz et al.   CANCER RESEARCH

CARTs on the Road for Myeloma

(2014) M. V. Maus et al.   CLINICAL CANCER RESEARCH

Targeting the bone marrow microenvironment in multiple myeloma

(2014) Yawara Kawano et al.   IMMUNOLOGICAL REVIEWS

Innate immune cells as homeostatic regulators of the hematopoietic niche

(2014) María Casanova-Acebes et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Unveiling Skeletal Fragility in Patients Diagnosed With MGUS: No Longer a Condition of Undetermined Significance?

(2014) Matthew T Drake   JOURNAL OF BONE AND MINERAL RESEARCH

Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myélome

(2014) Murielle Roussel et al.   JOURNAL OF CLINICAL ONCOLOGY

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

(2014) Jesús F San-Miguel et al.   LANCET ONCOLOGY

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

(2014) S Vincent Rajkumar et al.   LANCET ONCOLOGY

Diet-induced obesity promotes a myeloma-like condition in vivo

(2014) S T Lwin et al.   LEUKEMIA

Phospho-flow detection of constitutive and cytokine-induced pSTAT3/5, pAKT and pERK expression highlights novel prognostic biomarkers for patients with multiple myeloma

(2014) R Brown et al.   LEUKEMIA

PKA/AMPK signaling in relation to adiponectin’s antiproliferative effect on multiple myeloma cells

(2014) E A Medina et al.   LEUKEMIA

Bone marrow plasma macrophage inflammatory protein protein-1 alpha(MIP-1 alpha) and sclerostin in multiple myeloma: Relationship with bone disease and clinical characteristics

(2014) Xiao-Tao Wang et al.   LEUKEMIA RESEARCH

Engineered nanomedicine for myeloma and bone microenvironment targeting

(2014) A. Swami et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Current strategies for treatment of relapsed/refractory multiple myeloma

(2014) Jacob P Laubach et al.   Expert Review of Hematology

The role of epigenetics in the biology of multiple myeloma

(2014) K Dimopoulos et al.   Blood Cancer Journal

Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma

(2014) M A Dimopoulos et al.   Blood Cancer Journal

Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics

(2014) Antonio Garcia-Gomez   World Journal of Stem Cells

Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma

(2013) Rachid C. Baz et al.   AMERICAN JOURNAL OF HEMATOLOGY

Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma

(2013) H. Ludwig et al.   BLOOD

Chronic low dose tumor necrosis factor-α (TNF) suppresses early bone accrual in young mice by inhibiting osteoblasts without affecting osteoclasts

(2013) L.C. Gilbert et al.   BONE

In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma

(2013) Samantha Pozzi et al.   BONE

A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma

(2013) Maria T. Petrucci et al.   BRITISH JOURNAL OF HAEMATOLOGY

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Signaling Between Tumor Cells and the Host Bone Marrow Microenvironment

(2013) Natasa Kovacic et al.   CALCIFIED TISSUE INTERNATIONAL

Control of Bone Remodeling by the Peripheral Sympathetic Nervous System

(2013) Florent Elefteriou et al.   CALCIFIED TISSUE INTERNATIONAL

The Osteocyte: An Endocrine Cell … and More

(2013) Sarah L. Dallas et al.   ENDOCRINE REVIEWS

Zoledronic acid in the management of bone disease as a consequence of multiple myeloma: a review

(2013) Adrián Alegre et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

BM mesenchymal stromal cell–derived exosomes facilitate multiple myeloma progression

(2013) Aldo M. Roccaro et al.   JOURNAL OF CLINICAL INVESTIGATION

New insights into osteoporosis: the bone-fat connection

(2013) M. Kawai et al.   JOURNAL OF INTERNAL MEDICINE

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study

(2013) Meletios Dimopoulos et al.   LANCET ONCOLOGY

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

(2013) Jesus San Miguel et al.   LANCET ONCOLOGY

Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy

(2013) T Scullen et al.   LEUKEMIA

Macrophages in multiple myeloma: emerging concepts and therapeutic implications

(2013) Fotis Asimakopoulos et al.   LEUKEMIA & LYMPHOMA

Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease

(2013) Ida B. Kristensen et al.   LEUKEMIA & LYMPHOMA

Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk

(2013) Daniel Chubb et al.   NATURE GENETICS

WNT signaling in bone homeostasis and disease: from human mutations to treatments

(2013) Roland Baron et al.   NATURE MEDICINE

The Cost-Effectiveness of Initial Treatment of Multiple Myeloma in the U.S. With Bortezomib Plus Melphalan and Prednisone Versus Thalidomide Plus Melphalan and Prednisone or Lenalidomide Plus Melphalan and Prednisone With Continuous Lenalidomide Maintenance Treatment

(2013) L. P. Garrison et al.   ONCOLOGIST

Anti-Sclerostin Antibody Inhibits Internalization of Sclerostin and Sclerostin-Mediated Antagonism of Wnt/LRP6 Signaling

(2013) Maarten van Dinther et al.   PLoS One

Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study

(2013) M Offidani et al.   Blood Cancer Journal

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

(2012) D. S. Siegel et al.   BLOOD

Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features

(2012) A. K. Azab et al.   BLOOD

A prospective study of circulating adipokine levels and risk of multiple myeloma

(2012) J. N. Hofmann et al.   BLOOD

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

(2012) A. J. Jakubowiak et al.   BLOOD

Fluorescence-based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells

(2012) Karthik Ramasamy et al.   BRITISH JOURNAL OF HAEMATOLOGY

A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance

(2012) Dharminder Chauhan et al.   CANCER CELL

RANKL Expression, Function, and Therapeutic Targeting in Multiple Myeloma and Chronic Lymphocytic Leukemia

(2012) B. J. Schmiedel et al.   CANCER RESEARCH

Marrow Fat and the Bone Microenvironment: Developmental, Functional, and Pathological Implications

(2012) Clifford J. Rosen et al.   CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION

The Role of Adiponectin in Cancer: A Review of Current Evidence

(2012) Maria Dalamaga et al.   ENDOCRINE REVIEWS

A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma

(2012) Elisa Gallerani et al.   EUROPEAN JOURNAL OF CANCER

Polyphenols suppress hydrogen peroxide-induced oxidative stress in human bone-marrow derived mesenchymal stem cells

(2012) Haruyo Yagi et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

(2012) Laurent Garderet et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

(2012) Pieter Sonneveld et al.   JOURNAL OF CLINICAL ONCOLOGY

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects

(2012) M A Hurchla et al.   LEUKEMIA

Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation

(2012) N Giuliani et al.   LEUKEMIA

Plasma Cell Myeloma and Related Neoplasms

(2011) Robert B. Lorsbach et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Sclerostin is overexpressed by plasma cells from multiple myeloma patients

(2011) Giacomina Brunetti et al.   Annals of the New York Academy of Sciences

Disorders of Bone Remodeling

(2011) Xu Feng et al.   Annual Review of Pathology-Mechanisms of Disease

Effect of Obesity on Outcomes after Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

(2011) Dan T. Vogl et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial

(2011) A. J. Jakubowiak et al.   BLOOD

Do reactive oxygen species play a role in myeloid leukemias?

(2011) P. S. Hole et al.   BLOOD

Marrow fat metabolism is linked to the systemic energy metabolism

(2011) Beata Lecka-Czernik   BONE

Multiple Myeloma Mesenchymal Stem Cells: Characterization, Origin, and Tumor-Promoting Effects

(2011) M. R. Reagan et al.   CLINICAL CANCER RESEARCH

Antimyeloma Activity of a Multitargeted Kinase Inhibitor, AT9283, via Potent Aurora Kinase and STAT3 Inhibition Either Alone or in Combination with Lenalidomide

(2011) L. Santo et al.   CLINICAL CANCER RESEARCH

Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post-bortezomib monotherapy

(2011) Evangelos Terpos et al.   INTERNATIONAL JOURNAL OF CANCER

Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma

(2011) Masahiro Abe   INTERNATIONAL JOURNAL OF HEMATOLOGY

Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

(2011) David H. Henry et al.   JOURNAL OF CLINICAL ONCOLOGY

Evidence for osteocyte regulation of bone homeostasis through RANKL expression

(2011) Tomoki Nakashima et al.   NATURE MEDICINE

Illuminating Immune Privilege — A Role for Regulatory T Cells in Preventing Rejection

(2011) Tannishtha Reya   NEW ENGLAND JOURNAL OF MEDICINE

The Role of Bisphosphonates in Multiple Myeloma: Mechanisms, Side Effects, and the Future

(2011) S. Pozzi et al.   ONCOLOGIST

Concise Review: Mesenchymal Stem Cell Tumor-Homing: Detection Methods in Disease Model Systems

(2011) Michaela R. Reagan et al.   STEM CELLS

Myeloma cells suppress osteoblasts through sclerostin secretion

(2011) S Colucci et al.   Blood Cancer Journal

Chemomobilization with Etoposide is Highly Effective in Patients with Multiple Myeloma and Overcomes the Effects of Age and Prior Therapy

(2010) William A. Wood et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value

(2010) B. A. Walker et al.   BLOOD

Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs

(2010) I. G. Winkler et al.   BLOOD

Tumor–host cell interactions in the bone disease of myeloma

(2010) Jessica A. Fowler et al.   BONE

Denosumab and bisphosphonates: Different mechanisms of action and effects

(2010) Roland Baron et al.   BONE

Immunity, Inflammation, and Cancer

(2010) Sergei I. Grivennikov et al.   CELL

The anti-tumor effect of bisphosphonates ABCSG-12, ZO-FAST and more …

(2010) Michael Gnant et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Bisphosphonates as Treatment of Bone Metastases

(2010) Ingunn Holen et al.   CURRENT PHARMACEUTICAL DESIGN

Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma

(2010) N. Abildgaard et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma

(2010) J.-L. Harousseau et al.   HAEMATOLOGICA

Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial

(2010) A. Palumbo et al.   HAEMATOLOGICA

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

(2010) M. S. van der Veer et al.   HAEMATOLOGICA

Oral Bisphosphonate Use and Breast Cancer Incidence in Postmenopausal Women

(2010) Rowan T. Chlebowski et al.   JOURNAL OF CLINICAL ONCOLOGY

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

(2010) M. de Weers et al.   JOURNAL OF IMMUNOLOGY

Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells

(2010) Stephanie Markovina et al.   Molecular Cancer

Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia

(2010) Marc H. G. P. Raaijmakers et al.   NATURE

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

(2010) S. Vallet et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma

(2009) Rakesh Popat et al.   BRITISH JOURNAL OF HAEMATOLOGY

Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells

(2009) Thomas L. Andersen et al.   BRITISH JOURNAL OF HAEMATOLOGY

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and α2β interferon versus VBMCP

(2009) Robert A. Kyle et al.   CANCER

Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells

(2009) S. K. Martin et al.   HAEMATOLOGICA

Bone marrow changes in adolescent girls with anorexia nervosa

(2009) Kirsten Ecklund et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Treatment of Relapsed/Refractory Multiple Myeloma

(2009) Efstathios Kastritis et al.   SEMINARS IN HEMATOLOGY

The role of bisphosphonates in multiple myeloma

(2009) Jessica Levy et al.   Current Hematologic Malignancy Reports

Role of decorin in the antimyeloma effects of osteoblasts

(2008) X. Li et al.   BLOOD

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

(2008) Pieter Sonneveld et al.   CANCER

Inhibiting Dickkopf-1 (Dkk1) Removes Suppression of Bone Formation and Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma

(2008) Deborah J Heath et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies

(2008) Andrew G Renehan et al.   LANCET

Bone marrow microenvironment and the identification of new targets for myeloma therapy

(2008) K Podar et al.   LEUKEMIA

VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma

(2008) M Pineda-Roman et al.   LEUKEMIA

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

(2008) Paul Richardson et al.   LEUKEMIA & LYMPHOMA

RANK ligand as a therapeutic target for bone metastases and multiple myeloma

(2007) G. David Roodman et al.   CANCER TREATMENT REVIEWS